Read the full interview:
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.
Read moreWe are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.
Read moreCHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers
Read more